TRVI (Trevi Therapeutics) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TRVI Trevi Therapeutics Inc TRVI
22 GF Score
Price $17.93
! 3 Warning Signs
View Full Analysis

What is Trevi Therapeutics Net Loan?

Net Loan only applies to banks and insurance companies.

TRVI
22GF Score
Trevi Therapeutics Inc TRVI
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Trevi Therapeutics Business Description

Address 195 Church Street, 16th Floor, New Haven, CT, USA, 06510
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
22GF Score

Get the complete analysis for TRVI

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.93
Price